Enliven Therapeutics, Inc. - Common Stock (ELVN)

HC Wainwright initiated coverage on Enliven Therapeutics, noting its innovative small molecules for tumor treatments. HC Wainwright gave a Buy rating with a $37 price target, projecting significant sales potential for Enliven's therapies.

ELVN stock results show that Enliven Therapeutics beat analyst estimates for earnings per share the second quarter of 2024.

ELVN stock results show that Enliven Therapeutics beat analyst estimates for earnings per share the first quarter of 2024.

Enliven Therapeutics' Phase 1 trial results for ELVN-001 in chronic myeloid leukemia (CML) patients. Explore the promising safety and efficacy data.

Shares of Fastenal Company (NASDAQ: FAST) fell sharply during Thursday’s session following worse-than-expected first-quarter financial results.

U.S. stocks were mixed, with the Dow Jones index falling over 50 points on Thursday. Shares of Enliven Therapeutics, Inc. (NASDAQ: ELVN) rose sharply during Thursday’s session.

Mizuho Securities initiates coverage on Enliven Therapeutics. Expectations high for late 2024 Phase 1 results. Enliven poised to revolutionize CML treatment, addressing current TKI limitations. Mizuho bullish with Buy rating, $34 price target. ELVN's trading value suggests conservative estimation compared to CML market potential.

Shares of Peraso Inc. (NASDAQ: PRSO) fell sharply during Tuesday’s session after the company reported worse-than-expected fourth-quarter EPS results.

Stocks are scattered midday Tuesday, as investors digest the semiconductor sector's pullback that's being led by the shares of Nvidia.

U.S. stocks were mixed, with the Dow Jones index gaining around 75 points on Tuesday.

ELVN stock results show that Enliven Therapeutics beat analyst estimates for earnings per share the fourth quarter of 2023.

Investing in biotech stocks means accepting a long R&D window, but the rewards when your A-rated biotech stocks come through are huge.

Short interest on Mobileye Global fell from 23.9% to 21.2% in the week following the company’s Q1 results and FY23 guidance cut on April 27. However, Mobileye shares are up 31% from those lows over the past three weeks.

Biotech stocks have the potential for massive profits if their companies are successful in developing drugs that are safe and marketable.